thank you for pointing this out. we will correct. thanks tim
Timothy Cloughesy, MD Director and Professor UCLA Neuro-Oncology Program 710 Westwood Plaza, Suite 1-230 Los Angeles, CA 90095
That's his reply to my email to hi pointing out the mistake (DCVax Lung instead of DCVax L in the clinicaltrials.gov. He will correct to DCVax-L). see post 94157
Your guess that it's not DCVax L does not jive with his email. I don't have a thought out guess for why that's not corrected yet and I don't feel the need to muddy up the discourse. If you think my cut&paste of his email is some kind of funny business, you can write him yourself. That will help you get to the source. Easy to do. so no need to go that route.
Official Title: A Phase II Clinical Trial Evaluating Combination Therapy Using DCVax-L (Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen) and Nivolumab (an Anti-PD-1 Antibody) for Subjects With Recurrent Glioblastoma Multiforme
DCVax-L is a registered product. This "official title" does not mention anything about lung. It does mention GBM ... which seems would be unrelated to any lung vaccine. This title also mentions "Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen" ... which might not have anything to do with lung either.